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Abstract
Background: Osteoporosis is a complex disease with a strong genetic contribution. A recently published genome-
wide association study (GWAS) for estimated bone mineral density (eBMD) identified 1103 independent genome-
wide significant association signals. Most of these variants are non-coding, suggesting that regulatory effects may
drive many of the associations. To identify genes with a role in osteoporosis, we integrate the eBMD GWAS
association results with those from our previous osteoclast expression quantitative trait locus (eQTL) dataset.
Results: We identify sixty-nine significant cis-eQTL effects for eBMD GWAS variants after correction for multiple
testing. We detect co-localisation of eBMD GWAS and osteoclast eQTL association signals for 21 of the 69 loci,
implicating a number of genes including CCR5, ZBTB38, CPE, GNA12, RIPK3, IQGAP1 and FLCN. Summary-data-based
Mendelian Randomisation analysis of the eBMD GWAS and osteoclast eQTL datasets identifies significant
associations for 53 genes, with TULP4 presenting as a strong candidate for pleiotropic effects on eBMD and gene
expression in osteoclasts. By performing analysis using the GARFIELD software, we demonstrate significant
enrichment of osteoporosis risk variants among high-confidence osteoclast eQTL across multiple GWAS P value
thresholds. Mice lacking one of the genes of interest, the apoptosis/necroptosis gene RIPK3, show disturbed bone
micro-architecture and increased osteoclast number, highlighting a new biological pathway relevant to
osteoporosis.
Conclusion: We utilise a unique osteoclast eQTL dataset to identify a number of potential effector genes for
osteoporosis risk variants, which will help focus functional studies in this area.
Keywords: Osteoclast, Osteoporosis, GWAS, eQTL, BMD, Fracture, RIPK3, RIP3, FBN2, SNP
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: Benjamin.Mullin@uwa.edu.au
†John P. Walsh, Jiake Xu and Scott G. Wilson contributed equally to this
work.
1Department of Endocrinology & Diabetes, Sir Charles Gairdner Hospital,
Nedlands, WA, Australia
2School of Biomedical Sciences, The University of Western Australia, Crawley,
WA 6009, Australia
Full list of author information is available at the end of the article
Mullin et al. Genome Biology           (2020) 21:80 
https://doi.org/10.1186/s13059-020-01997-2
Background
Genome-wide association studies (GWAS) have success-
fully identified thousands of genetic variants associated
with complex traits and diseases in humans. However,
the vast majority of these variants lie in non-coding re-
gions of the genome such as intronic or intergenic DNA,
and it is thought that many of them influence the
phenotype through regulatory effects on nearby genes.
For many of these variants, the identity of the effector
gene responsible for the association remains to be deter-
mined. This is further complicated by the fact that the
closest gene to the GWAS association signal is not
always the effector gene, and in some cases, neither is
the most plausible biological candidate gene from the re-
gion. Expression quantitative trait locus (eQTL) studies
in disease-relevant cell/tissue types provide valuable
information on this issue by characterising associations
between genetic variants and expression of nearby genes.
The Genotype-Tissue Expression (GTEx) project pro-
vides extensive eQTL data for many tissues [1]; however,
not all cell types are represented in that resource and
many eQTL studies have used complex tissues contain-
ing a mixture of cell types. Apart from an eQTL study
performed on human osteoblasts cultured from surgical
explants of bone [2], there has historically been a lack of
eQTL studies performed in cell types relevant to osteo-
porosis. We recently generated a unique osteoclast-
specific eQTL resource using cells obtained from 158
subjects to fill the void of eQTL data for that cell type
and for the study of human bone disease [3, 4].
Bone is a dynamic tissue that is constantly being re-
modelled through the coupled actions of osteoblasts and
osteoclasts. Osteoporosis is the most common metabolic
bone disease in humans and is characterised by reduced
bone mineral density (BMD), micro-architectural dete-
rioration of the bone tissue and an increased risk of frac-
ture. Excess mortality caused by osteoporotic fracture
has been estimated at 9% in women and 24% in men at
1 year postfracture, and 24% in women and 26% in men
at 5 years postfracture [5]. Postmenopausal women are at
particularly high risk of developing osteoporosis due to
reduced oestrogen levels. Certain environmental factors
such as dietary calcium intake and exercise have also been
shown to influence an individual’s risk of developing the
disease [6, 7]. In addition to these factors, osteoporosis has
a strong heritable component, with twin and family stud-
ies generating heritability estimates of 0.46–0.84 for BMD
[8–10]. Individuals with an affected first-degree relative
have an elevated estimated familial relative risk for fragility
fracture of 1.31–4.24 [11, 12].
GWAS have proven to be very successful at identifying
genetic variants associated with bone parameters [13–18].
A recently published GWAS for estimated BMD (eBMD), a
trait calculated using quantitative ultrasound measurements
at the heel, included 426,824 individuals from the UK Bio-
bank and is the largest GWAS ever performed for a bone
density phenotype [19]. The study identified 1103 condi-
tionally independent genome-wide significant association
signals located in 518 loci, of which 301 are novel loci [19].
Like most complex disease GWAS, the majority of these
signals are led by non-coding variants. In order to identify
putative effector genes and genetic regulatory mechanisms
with a role in osteoporosis, particularly those that are rele-
vant to bone resorbing cells, we integrated the results from
that study with our osteoclast eQTL dataset and bone
phenotypes from knockout mice.
Results
Population characteristics of the 158 women recruited
into the osteoclast eQTL study cohort are presented in
Additional file 1: Table S1. All participants had self-
reported European ancestry, and principal components
analysis failed to identify any ethnic outliers. After geno-
type imputation and QC, genotype data was available for
5,373,348 variants in the study sample with a minor
allele frequency (MAF) ≥ 5% and an IMPUTE2 info
score ≥ 0.4. After applying QC criteria to the gene
expression dataset, a total of 15,688 expressed gene
transcripts were identified in the osteoclast-like cells.
Identification of eQTL associations for eBMD GWAS
variants
Of the 1103 lead genetic variants recently identified as
independently associated with eBMD at the genome-
wide significance level, 929 were present in the osteo-
clast eQTL dataset (MAF ≥ 5% in the cohort and had an
expressed gene located within the ± 1Mb analysis win-
dow). The vast majority of those missing were low fre-
quency variants with a MAF < 5% in the cohort. For the
929 variants present in the dataset, a mean of 15.0 genes
was present within the ± 1Mb analysis window.
After correction for multiple testing, we observed a
total of 69 significant eQTL associations for the eBMD
GWAS variants (Table 1, Fig. 1 and Additional file 1:
Table S2), with 61 of the variants associated with the
expression of 68 genes. Since variants with regulatory ef-
fects would be expected to be located in close proximity
to their respective eQTL-gene (eGene) transcription
start site (TSS), we examined this in our data. Of the 69
eQTL associations, 51 (74%) were for variants located
within 150 kb of the eGene TSS, with the average dis-
tance being 154.6 kb. The eQTL associations were also
stronger for variants located in close proximity to the as-
sociated gene, with the 10 strongest eQTL associations
identified all representing variants located within 155 kb
of the associated eGene TSS. eQTL associations were
observed for 8 of the genes identified in a previous
smaller study [3], including PIGV, ST7L, TRMT61B,
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DYSF, FADS2, GLDN, CYP19A1 and IQGAP1. Many of
the eQTL variants demonstrated significant associations
with expression of more than one gene, including
rs11677953 (RP11-378A13.1 and TMBIM1), rs2432236
(CTD-2376I4.1, CTD-2376I4.2 and FCHO2), rs42916
(LINC01184 and SLC12A2), rs11814082 (DDX10P1 and
ZNF438), rs7147775 (EIF2B2 and ACYP1), rs2899472
(GLDN and CYP19A1) and rs12325187 (ZNF200 and
ZNF174).
Co-localisation analysis
Since it is possible for independent GWAS and eQTL asso-
ciations to exist within a genetic locus, we decided to assess
co-localisation of eBMD GWAS and osteoclast eQTL asso-
ciation signals for each of the 69 significant eQTL loci using
the coloc package in R [21]. If the association signals within
the two datasets are shown to co-localise, it can be inter-
preted as strong evidence that the GWAS association is
mediated through regulatory effects on the eQTL gene.
Evidence of co-localisation of GWAS and eQTL association
signals was identified (posterior probability > 50%) in 19 of
the 69 loci, including CCR5 (82.1%), ZBTB38 (83.3%), CPE
(54.9%), GNA12 (50.1%), CALD1 (91.3%), METTL10
(96.6%), RIPK3 (89.8%) (Additional file 1: Fig. S1), EIF2B2
(65.9%), ACYP1 (83.4%), IQGAP1 (75.2%), FLCN (95.6%),
LLGL2 (78.1%), TMEM38A (71.1%), FKRP (84.0%), UBE2M
(82.6%), UBE2L3 (79.5%), FOXRED2 (55.0%), PPP6R2
(73.1%) and LINC01420 (87.2%). The eBMD GWAS associ-
ation signal at 14q24.3 led by rs7147775 demonstrated
strong evidence for co-localisation with eQTL effects for
both the EIF2B2 and ACYP1 genes (Additional file 1:
Fig. S2). Co-localisation analysis was also performed
using a newer, but as yet less widely evaluated version
of the coloc R functions, named coloc2, which is
thought to more fully address allelic heterogeneity
when present in the data [22]. Apart from CPE (3.0%)
and LLGL2 (1.0%), all of the genetic loci demonstrating
co-localisation in the coloc analysis also presented with
co-localisation using coloc2 (posterior probabilities 98.3–
100%). Two additional co-localised genetic loci were iden-
tified by coloc2, SFMBT1 (98.2%) and ZBED4 (99.1%).
eBMD GWAS and osteoclast eQTL results for all co-
localised loci are presented in Table 1, with those demon-
strating independent (non-co-localised) association signals
presented in Additional file 1: Table S2. An example of a
locus with independent eBMD GWAS and osteoclast
Table 1 Genetic loci demonstrating co-localised eBMD GWAS and osteoclast cis-eQTL associations
Variant Location EA OA EAF βGWAS Gene Expression
a Distance to TSS PeQTL βeQTL
rs4683184 chr3:46146215 G A 0.37 − 0.01 CCR5 22.96 ± 7.33 − 224,638 2.06E−04 − 0.47
rs13072536 chr3:52827195 T A 0.22 0.02 SFMBT1 2.87 ± 0.59 − 219,556 1.43E−04 0.50
rs1991431 chr3:141414608 A G 0.44 − 0.02 ZBTB38 7.13 ± 1.57 90,395 7.68E−05 0.44
rs1550270 chr4:165340648 C T 0.33 0.02 CPE 4.64 ± 3.7 − 20,546 7.29E−06 0.51
rs798545 chr7:2722752 T C 0.23 0.01 GNA12 21.9 ± 4.75 − 121,573 7.94E−05 0.53
rs2551769 chr7:135453583 A G 0.28 0.01 CALD1 1.23 ± 1.05 709,328 1.38E−05 − 0.58
rs11245388 chr10:124850559 T G 0.47 − 0.01 METTL10 1.06 ± 0.19 58,688 1.47E−11 0.72
rs3212240 chr14:24341692 C T 0.43 − 0.01 RIPK3 4.51 ± 1.07 1646 1.47E−06 − 0.55
rs7147775 chr14:75203508 G T 0.44 − 0.02 EIF2B2 4.62 ± 0.58 200,597 2.16E−09 − 0.62
rs7147775 chr14:75203508 G T 0.44 − 0.02 ACYP1 1.8 ± 0.56 134,024 4.75E−06 0.55
rs11073930 chr15:90503480 G C 0.46 − 0.02 IQGAP1 66.34 ± 9.26 115,262 1.46E−10 0.66
rs1736213 chr17:17231214 T G 0.43 0.01 FLCN 4.06 ± 0.89 − 5975 1.82E−09 − 0.54
rs1661725 chr17:75564053 C T 0.44 0.01 LLGL2 0.7 ± 0.24 38,973 9.98E−07 − 0.55
rs77420750 chr19:15868934 A C 0.31 0.01 TMEM38A 0.49 ± 0.29 − 792,194 1.43E−04 0.45
rs314675 chr19:46692822 C T 0.1 − 0.02 FKRP 1.45 ± 0.27 − 53,224 5.88E−06 0.92
rs73066226 chr19:58496846 C T 0.17 0.01 UBE2M 22.85 ± 3.39 − 62,115 1.71E−06 0.66
rs5754387 chr22:21620414 C G 0.17 − 0.02 UBE2L3 20.1 ± 2.88 70,967 1.82E−05 0.46
rs2294358 chr22:36375211 C G 0.07 0.04 FOXRED2 2.44 ± 1.37 − 131,893 1.55E−06 1.11
rs932536 chr22:49866824 A G 0.13 − 0.02 ZBED4 5.67 ± 0.67 12,982 8.39E−06 0.71
rs5770908 chr22:50439289 A G 0.29 − 0.02 PPP6R2 10.17 ± 1.8 95,985 1.36E−04 0.41
rs5914035 chrX:56981783 C T 0.23 0.02 LINC01420 13.14 ± 2.09 252,542 4.91E−06 0.62
EA effect allele, OA other allele, EAF effect allele frequency (derived from the osteoclast eQTL cohort), eBMD estimated BMD, TSS transcription start site; variant
locations derived from dbSNP build 150 (GRCh38/hg38), βGWAS values are relevant to the effect allele and were obtained from Morris et al. [19], βeQTL values are
given as the normalised effect size on gene expression for the effect allele. eQTL associations are significant using a multiple-testing corrected FDR of 5%
aExpression levels are stated as mean reads per kilobase million (RPKM) ± standard deviation
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eQTL association signals, LINC01184 (posterior probabil-
ity of co-localisation < 0.01% using coloc [21] and coloc2
[22]), is displayed in Additional file 1: Fig. S3.
Tissue-shared and osteoclast-specific eQTL associations
To establish the proportion of the identified eQTL
associations that have supporting evidence from other
tissue types and to identify those that are potentially
osteoclast-specific, we analysed each of the 69 eQTL
associations for evidence of replication in the 53 tis-
sues of the GTEx V7 dataset [1]. Only GTEx tissues
with > 70 samples were included in the analysis, with a
multiple-testing corrected false discovery rate (FDR) thresh-
old of 0.05 used to identify significant associations. Of the
69 eQTL associations, 45 (65.2%) demonstrated evidence of
association in at least one GTEx tissue, leaving 24 (34.8%)
as potentially specific to osteoclasts. These included the
eQTL associations for the genes HSPB7, NBPF3, ZNF593,
PIGV, KYAT3, HIBCH, CCR5, CPE, SLC12A2, PPP1R11,
CALD1, CBWD1, ZNF438, RP11-517P14.2, GLDN, ZNF1
74, NLRC3, HEATR3, RP11-104N10.2, TMEM38A, UBE
2M, SLX4IP, SNTA1 and LINC01420.
Summary-data-based Mendelian Randomisation analysis
In order to identify genes whose expression levels in osteo-
clasts are associated with the eBMD trait, we performed an
integrative analysis of the eBMD GWAS and osteoclast
eQTL datasets using the Summary-data-based Mendelian
Randomisation (SMR) software [23]. A total of 1070 genes
with an eQTL association significant at P < 5 × 10−8 were
identified and included in the analysis. Using a multiple-
testing corrected significance threshold of PSMR < 4.7 ×
10−5, the SMR test identified significant associations for 53
genes (Additional file 1: Table S3). Heterogeneity
(PHEIDI < 0.05) was detected for 52 of these, leaving a
single locus TULP4 as a strong candidate for harbouring
shared genetic effects (i.e. pleiotropy) on gene expression
in osteoclasts and eBMD (Additional file 1: Fig. S4). Ex-
pression of TULP4 was found to be positively associated
with eBMD (βSMR = 0.02, Additional file 1: Table S3).
Enrichment of osteoporosis risk variants within osteoclast
eQTL
We used the GWAS Analysis of Regulatory or Functional
Information Enrichment with LD correction (GARFIELD)
software [24] to determine whether osteoporosis risk
Fig. 1 CIRCOS plot [20] displaying (from outside to inside) chromosome numbers, chromosome ideograms, scatterplot complete with gene
labels representing the osteoclast eQTL associations presented in Table 1 and Additional file 1: Table S2 (red), scatterplot representing the eBMD
GWAS results (green) and gene ontology (GO) biological process groupings relevant to osteoclast biology. Osteoclast eQTL and eBMD GWAS
associations are displayed as −log10 P values ranging from 0.01 > P > 1.0 × 10
−15 (osteoclast eQTL) and 0.001 > P > 1.0 × 10−50 (eBMD GWAS). GO
biological process groupings displayed include membrane organisation (blue), regulation of cell migration (red), regulation of catalytic activity
(purple), cation transport (orange) and I-kappaB kinase/NF-kappaB signalling (green)
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variants in the eBMD GWAS summary result dataset are
enriched among high-confidence osteoclast eQTL variants
identified using a multiple-testing corrected FDR
threshold of 0.05. Using eBMD GWAS P value thresholds
of P < 1 × 10−5, 1 × 10−6, 1 × 10−7 and 1 × 10−8, we ob-
served significant enrichment of osteoporosis risk variants
within osteoclast eQTL (P = 3.25 × 10−40, 8.83 × 10−28,
6.93 × 10−24 and 7.79 × 10−18, respectively, Fig. 2). As a
comparison, we also performed enrichment analysis using
GWAS results from a similarly powered study for a trait
not considered to be related to bone biology, neuroticism
[25]. We observed nominally significant enrichment of
neuroticism GWAS variants within the osteoclast eQTL
dataset at the P < 1 × 10−7 and 1 × 10−8 thresholds (P = 0.01
and 0.007, respectively, Fig. 2); however, these were not
significant after correction for multiple testing.
Analysis of Ripk3 knockout mice
Among the genes identified in this study as potentially
relevant to osteoporosis is RIPK3. According to data
available in GTEx V7, the eBMD GWAS variant
rs3212240 is an eQTL for RIPK3 only in sun-exposed
skin (P = 2.0 × 10−5); however, data from this study sug-
gests that it is also relevant to bone cells. The C allele at
rs3212240, associated with a lower eBMD measurement,
was found to be associated with reduced expression of
the RIPK3 gene in our osteoclast eQTL dataset (Table 1).
Because of the strong evidence for co-localisation of
eBMD GWAS and osteoclast eQTL association signals
within this locus, combined with the known role of
RIPK3 in cellular necroptosis in response to the tumour
necrosis factor (TNF)-alpha family of death-inducing cy-
tokines and potential involvement in bone resorption in
osteoporosis [26], we performed in-depth skeletal phe-
notyping of Ripk3-deficient mice. Analysis of the distal
femur of 15-week-old male Ripk3−/− mice using micro-
CT revealed increased subperiosteal perimeter, increased
endosteal perimeter and increased bone marrow volume
compared to wildtype (WT) animals (Fig. 3). There was
no difference in cortical bone volume or trabecular indi-
ces between Ripk3−/− and WT mice (Additional file 1:
Fig. S5). However, the extent of trabecularisation along
the diaphysis was significantly reduced in the Ripk3−/−
mice (Fig. 3a).
Decalcified bone sections were stained for TRAP activ-
ity and with haematoxylin and eosin (H&E) to further
characterise the cellular features of the Ripk3−/− mice by
histomorphometry (Fig. 4a–f). Analysis of the TRAP-
stained bone sections revealed a significant increase in
the total number of osteoclasts, number of osteoclasts
Fig. 2 Analysis of the eBMD GWAS and osteoclast eQTL datasets using the GARFIELD software [24] demonstrated significant enrichment of
osteoporosis risk variants among osteoclast eQTL across four GWAS P value thresholds (P < 1 × 10−5, 1 × 10−6, 1 × 10−7 and 1 × 10−8), with the
enrichment results for the trait neuroticism [25] included for comparison. The upper panels present the −log10 enrichment P values for each
threshold, while the lower panels present the natural logarithm of the odds ratios for each threshold with 95% confidence intervals
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relative to bone surface and osteoclast surface relative to
bone surface in the Ripk3−/− bones relative to those from
the WT mice (Fig. 4a–c). No significant differences in
osteoblast parameters were observed between the
Ripk3−/− and WT bones (Fig. 4d, e). These results sug-
gest that Ripk3−/− mice present with increased osteoclast
number in vivo.
Discussion
In this study of human osteoclast-like cells, we have
identified a large number of genetic regulatory effects
for osteoporosis risk variants. The majority of the eQTLs
identified in this study are located in close proximity to
their effector gene TSS, consistent with findings from
the GTEx project [27]. A significant proportion (34.8%)
of the eQTL associations identified in this study are po-
tentially osteoclast-specific when compared with data
from the 53 tissues of the GTEx V7 dataset [1],
demonstrating the value of performing such investiga-
tions in disease-relevant cell/tissue types. We also found
that high-confidence osteoclast eQTLs are strongly
enriched for osteoporosis risk variants, with an average
3.5-fold enrichment seen across the four GWAS signifi-
cance thresholds tested.
An osteoporosis-relevant eQTL association was identi-
fied in this study for the eBMD GWAS variant
rs3212240, which was found to be significantly associ-
ated with expression of the RIPK3 gene, a member of
the receptor-interacting protein (RIP) family of serine/
threonine protein kinases. Co-localisation analysis of the
locus suggested that the eBMD GWAS and osteoclast
eQTL association signals may be driven by the same
causal variant. Analysis of Ripk3−/− mice revealed a var-
iety of bone effects, primarily characterised by expansion
of the femoral shaft with reduced extension of the tra-
becular network and an increase in marrow volume. The
Fig. 3 Micro-CT assessment of the distal femur from 15-week-old male Ripk3−/− and WT mice. Representative 3D images of the distal femur
demonstrate the following: a reduced extension of the trabecular network into the diaphysis, b expansion of the medullary cavity and c
increased size of the trabecular bone compartment with no change in trabecular bone density in the Ripk3-/- mice. Quantitative analysis of micro-
CT parameters (mean + standard deviation) displays the following: d cortical volume, e bone marrow volume, f endosteal perimeter, g periosteal
perimeter, h trabecular bone volume fraction and i trabecular extension in the Ripk3−/− mice relative to WT mice. N = 5 for each group; WT,
wildtype. **P < 0.01
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effects observed on trabecular extension could poten-
tially account for the association with eBMD in humans,
a phenotype derived using quantitative ultrasound mea-
surements at the heel and hence primarily influenced by
bone structural parameters including the orientation of
the trabecular bone [28], as opposed to BMD. The lead
eBMD GWAS variant from the human RIPK3 locus,
rs3212240, does not demonstrate even nominal associa-
tions with total body [14], femoral neck or lumbar spine
[18] BMD derived using dual-energy X-ray absorp-
tiometry. The product of the RIPK3 gene is a component
of the TNF receptor 1 signalling complex and has an
established role in necroptosis [29, 30], a type of pro-
grammed cell death thought to cause inflammation
through the release of intracellular factors [31]. Our his-
tomorphometric analysis of the Ripk3−/− bones revealed
increased numbers of osteoclasts relative to WT bones,
suggesting that this gene may have a role in osteoclast
necroptosis and that loss of this mechanism may lead to
an excess of osteoclasts. If this is the case, it could po-
tentially explain why the C allele at rs3212240 is
associated with reduced expression of the RIPK3 gene in
our osteoclast eQTL dataset and a reduced eBMD [19].
The variant rs3212240 is located ~ 1.5 kb upstream of
the RIPK3 TSS and is in moderate linkage disequilib-
rium (LD) (r2 = 0.50) with a nearby body height GWAS
variant (rs1950500) [32]. It is also in moderate LD (r2 =
0.79) with a missense variant in an adjacent gene,
NFATC4 (rs2229309), and we cannot rule out the possi-
bility that the association at this locus with eBMD is par-
tially mediated through the effects of this variant.
However, rs2229309 is classified as benign by various
pathogenicity prediction algorithms [33–35]. Consider-
ing the strong regulatory effect on RIPK3 demonstrated
for rs3212240, combined with the altered bone pheno-
types observed in Ripk3−/− mice, we consider that the as-
sociation at this locus with eBMD is likely to be
mediated through regulatory effects on the RIPK3 gene.
A novel eQTL association relevant to osteoporosis was
identified in this study for the CPE gene. This locus also
presented with evidence for co-localisation of eBMD
GWAS and osteoclast eQTL association signals using
Fig. 4 Quantitative histomorphometric analysis of femora from 15-week-old male WT and Ripk3−/− mice (mean + standard deviation). a Osteoclast
number (N.Oc). b Osteoclast surface relative to bone surface (Oc.S/BS). c Number of osteoclasts relative to bone surface (N.Oc/BS(mm−1)). d
Osteoblast number (N.Ob). e Number of osteoblasts relative to bone surface (N.Ob/BS(mm−1)). f Representative low-power images (× 40
magnification) of TRAP-stained sections of the femur just below the growth plate. N = 4 and 5 for the WT and Ripk3−/− groups, respectively;
WT, wildtype
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the coloc package [21] and was identified as a significant
locus in the SMR analysis. Of note, the association seen
in our data between the eBMD GWAS variant
rs1550270 and expression of CPE was not observed in
any of the 53 tissues of the GTEx V7 dataset [1]. The
product of the CPE gene, carboxypeptidase E, is a
prohormone-processing enzyme that cleaves carboxy-
terminal basic residues from neuropeptide intermediates
and peptide hormones to produce mature bioactive
products, including insulin [36]. The CPE gene has been
strongly implicated in diabetes, with mutation in the hu-
man CPE gene identified as the likely cause of a genetic
disease characterised by obesity, type 2 diabetes, intellec-
tual disability and hypogonadotrophic hypogonadism
[37]. A deactivating mutation in the murine Cpe gene
also results in a pronounced obesity-diabetes syndrome
[38]. Cpe-knockout mice present with obesity and re-
duced BMD with increased plasma levels of osteocalcin
and carboxy-terminal collagen crosslinks, indicating the
presence of increased bone turnover [39]. Expression of
receptor activator of nuclear factor kappa-B ligand
(RANKL) was found to be elevated approximately 2-fold
relative to osteoprotegerin in the femora of Cpe-deficient
mice, potentially leading to increased osteoclast activity
[39]. It has also been established that expression of Cpe
is highly upregulated in mouse osteoclasts compared to
their precursor cells and that this upregulation is associ-
ated with increased formation of TRAP-positive multi-
nucleated osteoclasts and expression of key genes
involved with osteoclastogenesis [40]. Our osteoclast
eQTL data indicates that the human CPE gene has a role
in bone density regulation and highlights this gene as a
potential pleiotropic locus relevant to diabetes and
osteoporosis.
We observed some interesting eQTL effects in this
study for several genes implicated in monogenic disor-
ders. An example of this is the FBN2 gene, encoding
fibrillin 2, which is an extracellular protein that is a
major component of connective tissue microfibrils.
Mutation in this gene has been identified as the cause of
congenital contractural arachnodactyly (CCA) [41], a
disorder phenotypically similar to Marfan syndrome
(caused by mutation in the related gene FBN1). CCA is
characterised by a variety of skeletal abnormalities in-
cluding congenital contractures, arachnodactyly, deform-
ities of the chest wall, scoliosis and elongated limbs.
Another example is the gene FLCN, encoding folliculin,
which was identified as a significant locus in the SMR
analysis and demonstrated strong evidence for co-
localisation of eBMD GWAS and osteoclast eQTL asso-
ciation signals. Folliculin has recently been shown to
regulate osteoclastogenesis through metabolic effects on
oxidative phosphorylation and purine metabolism [42].
Induced deletion of the murine Flcn gene in osteoclast
precursors was found to result in severe osteoporosis
caused by excess osteoclastogenesis [42]. Mutation in
the human FLCN gene has been identified as the cause
of Birt-Hogg-Dubé syndrome [43], an autosomal dom-
inant condition characterised by early onset renal tu-
mours, hair follicle hamartomas, pulmonary cysts and
spontaneous pneumothoraces. However, we are not
aware of any significant bone or skeletal phenotypes
that have been reported in instances of this condition
to date.
The SMR analysis identified a significant association
for the TULP4 gene, with the HEIDI test suggesting that
the locus may exhibit pleiotropic effects on TULP4 ex-
pression and eBMD. The product of the TULP4 gene
has not been extensively characterised with regard to a
role in bone biology; however, it is thought to be a cyto-
plasmic protein characterised by a large amino terminus
containing a WD40 repeat region and a suppressor of
cytokines signalling domain [44]. TULP4 has been impli-
cated in the formation of orofacial clefts [45] and is a
body height GWAS locus [32, 46]. Mutation in the re-
lated gene WDR35 has been implicated in cranioectoder-
mal dysplasia, also known as Sensenbrenner syndrome,
an autosomal recessive condition characterised by cra-
niofacial and skeletal abnormalities [47]. The top eQTL
variant identified for TULP4 is rs341106, which is only
in weak LD with the lead eBMD GWAS variant from
the locus rs12206717 (r2 = 0.02 in Europeans [48]).
rs12206717 is a missense variant in exon 9 of TULP4,
which causes a change of amino acid 522 from serine to
asparagine. It is possible that there are 2 independent as-
sociation signals for eBMD arising from the locus, one
potentially causing a structural change in the TULP4
protein and the other influencing expression of the gene.
It is worth noting that the differentiated osteoclast-like
cells used in this study likely express a smaller panel of
genes when compared to complex tissues containing a
mixture of cell types such as those used in the GTEx
project. When this is considered in the context of a rela-
tively modest sample size, it potentially explains why a
greater number of co-localised genetic loci were not
identified in this study. It is also possible that the eBMD
GWAS data are primarily reflective of bone accrual and
osteoblast function and that resorption and osteoclast
activity are not the primary drivers of those results. It
should also be noted that the threshold used to identify
co-localised loci (posterior probability > 50%) is merely a
guideline and that probabilities below this value do not
necessarily indicate independent association signals, par-
ticularly when considering the sample size of the osteo-
clast eQTL cohort. The SMR software may also be
susceptible to small-sample biases, which could poten-
tially explain the large proportion of significant HEIDI
test scores seen in the study.
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Conclusions
We have used a unique osteoclast-specific eQTL dataset
to identify a number of genetic regulatory effects rele-
vant to osteoporosis. Approximately one third of these
regulatory effects were not seen in the 53 tissues of the
GTEx V7 dataset [1] and are potentially osteoclast-
specific. A number of the genes highlighted in this study
present strongly as having a potential role in bone biol-
ogy, including CPE, FBN2, FLCN and RIPK3, and our re-
sults support the growing body of evidence suggesting
that the CPE gene may exert pleiotropic effects on type
2 diabetes and osteoporosis. We performed thorough
skeletal phenotyping of Ripk3-deficient mice, which pre-
sented with altered bone micro-architectural characteris-
tics potentially driven through effects on osteoclast
necroptosis. The results from this study have identified a
number of potential effector genes for GWAS loci rele-
vant to osteoporosis, which will help target future trans-
lational studies.
Materials and methods
Subject recruitment and generation of osteoclast-like
cells
Details of the recruitment process and cell culture pro-
cedures used in this study have been described previ-
ously [3]. Briefly, the osteoclast eQTL study cohort
comprises 158 women aged 30–70 years with self-
reported European ancestry who attended the Bone
Density Unit at Sir Charles Gairdner Hospital in West-
ern Australia for a dual-energy X-ray absorptiometry
BMD scan in 2016 (Hologic, Bedford, MA, USA). Exclu-
sion criteria used during recruitment included presence
of medical conditions or use of medications that are
likely to influence osteoclastic bone resorption or the
process of osteoclastogenesis. Osteoclast-like cells were
generated using the conventional procedure; peripheral
blood mononuclear cells were first isolated from blood
samples obtained from each individual by density gra-
dient centrifugation using protocols well established in
our laboratory [3, 49]. These cells were cultured in tripli-
cate for 2 days in α-MEM supplemented with 25 ng/ml
macrophage colony stimulating factor (M-CSF), then for
a further 12 days in α-MEM supplemented with 25 ng/
mlM-CSF and 100 ng/ml RANKL while osteoclastogen-
esis occurred. The osteoclastic character of the cultures
was verified by staining for tartrate-resistant acid phos-
phatase (TRAP) as described previously [3] and by gene
expression profiling (Additional file 1: Fig. S6).
Nucleic acid extraction
Genomic DNA for each participant was extracted from
whole blood using the QIAamp DNA Blood Mini Kit
(QIAGEN) according to the manufacturer’s instructions.
At day 14 of culture, RNA and DNA were harvested
from each set of triplicate osteoclast-like cell cultures
using the AllPrep DNA/RNA Mini Kit (QIAGEN) ac-
cording to the manufacturer’s instructions, with on-
column DNase digestion for the RNA fraction. High-
quality RNA was obtained, with all samples recording
RNA integrity numbers (RINs) ≥ 9.7.
Genotyping and imputation
Genome-wide array genotyping was performed on the
genomic DNA samples using the Illumina Infinium
OmniExpress-24 BeadChip array. QC criteria applied to
the genotype data included removal of individuals with a
call rate < 90%, variants that were monomorphic, un-
mapped, had a MAF < 5%, Hardy-Weinberg equilibrium
P < 5 × 10−8 or call rate < 90%, leaving 572,898 variants
for imputation. Genotype imputation was then per-
formed by the Sanger Imputation Service using the
Haplotype Reference Consortium (HRC) release 1.1 ref-
erence panel [50]. Any variants with an IMPUTE2 info
score < 0.4 were removed from the imputed dataset. Re-
latedness testing and principal components analysis was
performed on the genotype dataset using Plink v1.9 [51],
with 10 principal components generated for use as co-
variates in the eQTL analysis to correct for population
stratification.
Generation and processing of gene expression data
Transcriptome-wide quantitation of gene expression was
performed on the osteoclast RNA samples using 50 bp
single-end RNA-Seq on an Illumina HiSeq 2500. Raw
read counts were generated for each gene (GENCODE
v25), while those displaying a read count < 1 per million
or expressed in < 10 individuals were removed. Trimmed
mean of M value (TMM) normalisation and correction
for total read count by conversion to counts per million
(CPM) was performed on the gene expression data using
the edgeR package [52]. Reads per kilobase per million
(RPKM) values were also calculated for each gene using
edgeR [52] to enable comparison of expression levels
between different genes.
eQTL association analysis
The top genetic variant at each of the 1103 recently
identified independent association signals for eBMD [19]
was investigated for cis- (local) eQTL effects in the
osteoclast samples. The eQTL analysis was performed
on the TMM-normalised CPM gene expression values
using the FastQTL software [53], which performs linear
regressions between genotypes and gene expression
values. Quantile normalisation was implemented using
FastQTL (based on the rntransform function of the Gen-
ABEL package [54]) to ensure the gene expression values
were normally distributed with a mean of 0 and standard
deviation of 1. Only variants with a MAF ≥ 5% were
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included in the analysis, which was adjusted for the co-
variates patient age, RNA-Seq batch and 10 genomic
principal components. Each variant was tested for asso-
ciation with the expression of any gene with a TSS lo-
cated within a 1Mb window on either side of the
variant, consistent with the methods used by the GTEx
project. Correction for multiple testing was performed
using the Benjamini-Hochberg procedure [55], utilising
a FDR of 5%.
Co-localisation analysis
To assess the probability that eBMD GWAS and osteo-
clast eQTL association signals residing in the same locus
share the same causal variant, we performed a co-
localisation analysis of the two datasets using the coloc
package in R (default settings) [21]. This software uses a
Bayesian framework to calculate posterior probabilities
for 5 different scenarios (hypotheses) regarding the pres-
ence and sharing of causal variants between two genetic
association datasets using summary statistics. A poster-
ior probability of > 50% for hypothesis H4 for a specific
locus (association with trait 1 and trait 2, one shared
variant) indicates that co-localisation of the association
signals in the two datasets due to a shared causal variant
is the most likely of the 5 scenarios. We also performed
co-localisation analysis using an updated version of the
coloc software, named coloc2 [22]. Coloc2 performs
alignment of the GWAS and eQTL summary results for
each cis-eQTL region as a pre-processing step and in-
cludes optional changes implemented in the gwas-pw al-
gorithm [56].
Summary-data-based Mendelian Randomisation analysis
To further characterise functionally relevant genes for
the eBMD GWAS associations and to identify potential
pleiotropic effects on gene expression and eBMD, we
performed integration of the complete set of eBMD
GWAS summary results with the osteoclast eQTL data-
set (± 1Mb) using the SMR software [23]. This package
applies the principles of Mendelian randomisation [57]
to test for association between gene expression and a
trait due to a shared variant at a genetic locus. The soft-
ware performs an SMR test, which detects dual associ-
ation signals in the GWAS and eQTL datasets by testing
for association between gene expression and the trait of
interest at the top associated eQTL for each gene. The
software also performs a heterogeneity in dependent in-
struments (HEIDI) test, which compares the association
signals for nearby co-inherited markers in the GWAS
and eQTL datasets. A significant HEIDI test indicates
heterogeneity in the association profiles of the two data-
sets, thereby suggesting that the association signals seen
in each dataset are less likely to be driven by the same
causal variant. The osteoclast eQTL cohort genotype
dataset was used as the reference panel in these analyses
for estimation of LD, and only genes with at least 1 cis-
eQTL association at P < 5 × 10−8 were included (N =
1070). A Bonferroni multiple-testing corrected signifi-
cance threshold of P < 4.7 × 10−5 was used for the SMR
test (PSMR), while a conservative significance threshold
of P < 0.05 was set for the HEIDI test (PHEIDI) as an
indicator of heterogeneity.
Osteoclast eQTL enrichment analysis
The GARFIELD software [24] was used to test for en-
richment of osteoporosis risk variants among high-
confidence osteoclast eQTL. GARFIELD performs LD
pruning (r2 > 0.1) of GWAS association results to gener-
ate an independent set of variants and then integrates
this with annotations containing regulatory or functional
information. Each variant is annotated to a functional
category or regulatory feature if the variant or an LD
proxy (r2 > 0.8) is part of that annotation group. Fold en-
richment is calculated using odds ratios at specified
GWAS P value thresholds with significance assessed
using a generalised linear model while accounting for
MAF, distance to nearest TSS and number of LD
proxies. A custom annotation category was generated
containing all significant osteoclast eQTL associations
identified at FDR 5%. Enrichment of eBMD GWAS
variants in this annotation was assessed at four GWAS
significance thresholds: P < 1 × 10−5, 1 × 10−6, 1 × 10−7
and 1 × 10−8. The UK10K variant set was used as the ref-
erence population for these analyses, with correction for
multiple testing performed using the Bonferroni method.
X-ray microcomputed tomography analysis of mouse
bones
Ripk3-deficient mice were generated and phenotyped as
described previously [58]. Femora were cleaned of soft
tissue and fixed in 10% neutral buffered formalin for 48
h, followed by 24 h immersion in phosphate-buffered sa-
line (PBS). Five pairs of 15-week-old male Ripk3−/− mice
and WT controls were used for the micro-CT analysis.
Fixed femora were immersed in PBS and immobilised in
a 2-ml tube prior to scanning of the distal femur using a
Skyscan 1176 micro-CT instrument (Bruker, Kontich,
Belgium). Scan parameters were as follows: 50 kV,
500 μA, 0.5 mm Al filter, exposure time 1 s, 0.4° rotation
step, frame averaging of 2 and pixel resolution 8.89 μm.
Scans were reconstructed using NRecon software (Bru-
ker, Kontich, Belgium) using a constant threshold value
and then analysed using the CTAn software (Bruker,
Kontich Belgium). A trabecular region of interest was
defined 0.5 mm below the base of the growth plate and
1mm in height. A cortical region of interest was defined
3 mm below the growth plate and 1mm in height. Tra-
becular extent was defined as the distance from the base
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of the growth plate to the furthest definable continuous
trabecular element. Reported trabecular values were
bone volume/tissue volume (BV/TV), trabecular thick-
ness (Tb.Th), trabecular separation (Tb.Sp), trabecular
number (Tb.N), trabecular extension (Tb.Ex) and BMD;
reported cortical values were cortical thickness (Ct.Th),
cortical bone volume (Ct.BV), marrow volume (Ma.V),
endocortical perimeter (Ec.Pm), periosteal perimeter
(Ps.Pm) and tissue mineral density (TMD). Differences
between WT and Ripk3−/− samples were assessed using
an unpaired t test.
Histomorphometric analysis of mouse bones
Mouse femur samples were formalin-fixed, decalcified
and embedded in paraffin before being subjected to
staining with H&E and a chromogenic TRAP substrate
to characterise in vivo osteoblast and osteoclast parame-
ters. Stained bone sections were scanned using a Scan-
scope XT machine (Aperio) at × 20 objective, with
histomorphometric analysis performed using the Bio-
Quant Osteo software (BioQuant). To characterise the
trabecular bone, a region of interest located approxi-
mately 500 μm below the growth plate at the distal
femur and 1mm in height was defined. For the cortical
bone analysis, we used a region located approximately 4
mm below the growth plate with a height of 1 mm. Two
sections were analysed for each femur, with the mean of
the two sets of measurements used for statistical ana-
lysis. Differences between the WT and Ripk3−/− groups
were assessed using an unpaired t test.
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